SPHK1 and cervical cancer: In pCCa-1 and pCCa-2 primary cervical cancer cells, treatment with SKI-V (10 μM, 6h) robustly decreased the SphK activity (Figure 4A), and induced ceramide accumulation (Figure 4B).